State Street SPDR S&P Biotech ETF (XBI)
ETF · Equity · SPDR · Data as of 2026-10-22
Bottom line
XBI is a SPDR fund that holds companies in one industry, for 0.35% a year. Over the past year its price rose 38.4%, 24.6 points ahead of the S&P 500. It pays about 0.4% a year, twice a year. Past returns are not a guarantee of future results.
Fund facts
Fee: 0.35% a year
Assets: $10.3B
Holdings: 165
Payouts, past 12 months: 0.36%
Past year
38.41% price · 38.99% with payouts
About the fund
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
Related funds
- VanEck Semiconductor ETF (SMH)
- iShares Semiconductor ETF (SOXX)
- VanEck Gold Miners ETF (GDX)
- First Trust Nasdaq Cybersecurity ETF (CIBR)
- iShares Expanded Tech-Software Sector ETF (IGV)
- Global X - U.S. Infrastructure Development ETF (PAVE)
- iShares U.S. Aerospace & Defense ETF (ITA)
- iShares Biotechnology ETF (IBB)
一句话结论
XBI 是 SPDR 旗下持有单一细分行业公司的基金，年费率 0.35%。过去一年价格上涨 38.4%，领先标普 500 24.6 个百分点。每年派息约 0.4%，每半年派发。过往表现并不能保证未来的结果。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.